CABA

Company Overview — What Does Cabaletta Bio, Inc. Do?

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Cabaletta Bio, Inc. (CABA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Steven Nichtberger and employs approximately 50 people. With a market capitalization of $298M, CABA is one of the notable companies in the Healthcare sector.

Cabaletta Bio, Inc. (CABA) Stock Rating — Reduce (April 2026)

As of April 2026, Cabaletta Bio, Inc. receives a Reduce rating with a composite score of 33.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CABA ranks #2,343 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cabaletta Bio, Inc. ranks #280 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CABA Stock Price and 52-Week Range

Cabaletta Bio, Inc. (CABA) currently trades at $3.13. The stock lost $0.04 (1.1%) in the most recent trading session. The 52-week high for CABA is $3.78, which means the stock is currently trading -17.1% from its annual peak. The 52-week low is $0.99, putting the stock 218.0% above its annual trough. Recent trading volume was 909K shares, suggesting relatively thin trading activity.

Is CABA Overvalued or Undervalued? — Valuation Analysis

Cabaletta Bio, Inc. (CABA) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.05x, versus the sector average of 2.75x.

At current multiples, Cabaletta Bio, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cabaletta Bio, Inc. Profitability — ROE, Margins, and Quality Score

Cabaletta Bio, Inc. (CABA) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -139.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -94.8% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CABA Debt, Balance Sheet, and Financial Health

Cabaletta Bio, Inc. has a debt-to-equity ratio of 47.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.77x, indicating strong short-term liquidity. Total debt on the balance sheet is $5M. Cash and equivalents stand at $60M.

CABA has a beta of 1.59, meaning it is more volatile than the broader market — a $10,000 investment in CABA would be expected to move 58.9% more than the S&P 500 on any given day. The stability factor score for Cabaletta Bio, Inc. is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cabaletta Bio, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cabaletta Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.10. Net income for the quarter was $-157M. Operating income came in at $-163M.

In FY 2025, Cabaletta Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.10. Net income for the quarter was $-168M. Operating income came in at $-172M.

In Q3 2025, Cabaletta Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.44. Net income for the quarter was $-45M. Operating income came in at $-47M.

In Q2 2025, Cabaletta Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.73. Net income for the quarter was $-45M. Operating income came in at $-46M.

Over the past 8 quarters, Cabaletta Bio, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing CABA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CABA Dividend Yield and Income Analysis

Cabaletta Bio, Inc. (CABA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CABA Momentum and Technical Analysis Profile

Cabaletta Bio, Inc. (CABA) has a momentum factor score of 68/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 46/100 reflects moderate short selling activity.

CABA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cabaletta Bio, Inc. (CABA) ranks #280 out of 838 stocks based on the Blank Capital composite score. This places CABA in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CABA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CABA vs S&P 500 (SPY) comparison to assess how Cabaletta Bio, Inc. stacks up against the broader market across all factor dimensions.

CABA Next Earnings Date

No upcoming earnings date has been announced for Cabaletta Bio, Inc. (CABA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CABA? — Investment Thesis Summary

The quantitative profile for Cabaletta Bio, Inc. suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Price momentum is positive at 68/100, suggesting the trend favors buyers. High volatility (stability score 22/100) increases portfolio risk.

In summary, Cabaletta Bio, Inc. (CABA) earns a Reduce rating with a composite score of 33.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CABA stock.

Related Resources for CABA Investors

Explore more research and tools: CABA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CABA head-to-head with peers: CABA vs AZN, CABA vs SLGL, CABA vs VMD.